SCHEMBL1259535

SCHEMBL1259535

Cc1ccc(C#N)nc1-c1cccc(F)c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 5/20 0.49
ADORA2A P29274 4/20 0.49
ADORA2B P29275 2/20 0.49
CHUK O15111 1/20 0.45
KDM4E B2RXH2 1/20 0.42
HPGD P15428 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
MGAM O43451 1/20 0.40
GAA P10253 1/20 0.40
SI P14410 1/20 0.40
MGAM2 Q2M2H8 1/20 0.40
DPP4 P27487 1/20 0.39
CTSS P25774 1/20 0.38
GABRG2 P18507 1/20 0.38
GABRB3 P28472 1/20 0.38
GABRA5 P31644 1/20 0.38
GABRA3 P34903 1/20 0.38
GRM5 P41594 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1259949 0.81 ALDH1A1 (0.44) ADORA1ADORA2AADORA2BCHUKKDM4E
SCHEMBL2974448 0.80 CHEK1 (0.49) ADORA1ADORA2AADORA2BKDM4EHPGD
SCHEMBL13623157 0.76 ADORA2A (0.51) ADORA1ADORA2AADORA2BCHUKKDM4E
SCHEMBL3790714 0.74 ALDH1A1 (0.51) KDM4ENPSR1
SCHEMBL4145506 0.73 CLK2 (0.45) ADORA1ADORA2AADORA2BCHUK
SCHEMBL603342 0.73 KDM4E (0.48) ADORA1ADORA2AADORA2BCHUKKDM4E
SCHEMBL15832010 0.73 ADORA1 (0.49) ADORA1ADORA2AADORA2BCHUKKDM4E
SCHEMBL23621181 0.72 ADORA1 (0.46) ADORA1ADORA2AADORA2BCHUKKDM4E
SCHEMBL14153105 0.71 GABRG2 (0.48) ADORA1ADORA2AADORA2BKDM4EHPGD
SCHEMBL9514248 0.71 CLK4 (0.46) ADORA1ADORA2AADORA2BKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8445509-B2 Fused heterocyclic derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-21 US disclosed
US-8445509-B2 Fused heterocyclic derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-21 US disclosed
US-8445509-B2 Fused heterocyclic derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-21 US disclosed
US-20110046169-A1 FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-24 US disclosed
US-20110046169-A1 FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-24 US disclosed
US-20110046169-A1 FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-24 US disclosed
WO-2009136663-A1 FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046169-A1 FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF ABL1, MAP4K2, MAP3K20 ADORA1 4115/4885ADORA2A 2942/4885ADORA2B 3742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.